BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-10 15:04 |
Announces U.S. FDA Acceptance of New Drug Application for APHEXDA®
(motixaforti…
|
English | 36.2 KB | ||
| 2022-11-06 15:55 |
Receipt of Nasdaq Minimum Bid Price Notification
|
English | 77.9 KB | ||
| 2022-11-06 15:55 |
Receipt of Nasdaq Minimum Bid Price Notification
|
English | 36.0 KB | ||
| 2022-11-03 16:31 |
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Mul…
|
English | 144.9 KB | ||
| 2022-11-03 16:31 |
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Mul…
|
English | 36.3 KB | ||
| 2022-09-28 00:33 |
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in …
|
English | 139.3 KB | ||
| 2022-09-28 00:33 |
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in …
|
English | 36.1 KB | ||
| 2022-09-21 17:20 |
FORM 6-K- BioLineRx completed $15 Million direct offering of ADSs and warrants
|
English | 493.6 KB | ||
| 2022-09-21 17:20 |
FORM 6-K- BioLineRx completed $15 Million direct offering of ADSs and warrants
|
English | 35.9 KB | ||
| 2022-09-21 01:48 |
PROSPECTUS SUPPLEMENT dated September 18, 2022
|
English | 508.3 KB | ||
| 2022-09-21 01:48 |
PROSPECTUS SUPPLEMENT dated September 18, 2022
|
English | 35.9 KB | ||
| 2022-09-19 17:11 |
BioLineRx Announces $15 Million Registered Direct Offering
|
English | 68.8 KB | ||
| 2022-09-19 17:11 |
BioLineRx Announces $15 Million Registered Direct Offering
|
English | 36.0 KB | ||
| 2022-09-15 15:59 |
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreo…
|
English | 196.6 KB | ||
| 2022-09-15 15:59 |
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreo…
|
English | 36.1 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
